Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N04 ANTI-PARKINSON DRUGS
N04B DOPAMINERGIC AGENTS
N04BC Dopamine agonists
N04BC09 Rotigotine
D05768 Rotigotine (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antiparkinson Agents
Dopamine Agonists
Rotigotine
D05768 Rotigotine (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
116 Antiparkinsonian agents
1169 Others
D05768 Rotigotine (JAN/USAN/INN)
119 Miscellaneous
1190 Miscellaneous
D05768 Rotigotine (JAN/USAN/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01472 Dopamine agonist
DG01468 Dopamine D2-receptor agonist
D05768 Rotigotine
DG01967 Antiparkinson agent
D05768 Rotigotine
Drug classes [BR:br08332]
Neuropsychiatric agent
DG01967 Antiparkinson agent
D05768 Rotigotine
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD2
D05768 Rotigotine (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D05768
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D05768
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D05768
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D05768